A Comparison of Biochemical Relapse-free Survival and Initiation of Salvage Therapy in Patients With Intermediate-risk Prostate Cancer Treated With Radical Prostatectomy, External Beam Radiotherapy, or Permanent Seed Implantation

2007 ◽  
Vol 69 (3) ◽  
pp. S327-S328
Author(s):  
A.D. Vassil ◽  
E.S. Murphy ◽  
C.A. Reddy ◽  
A. Altman ◽  
N. Chehade ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Intermediate Risk ◽  
Biochemical Relapse ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Seed Implantation ◽  
Risk Prostate Cancer

scholarly journals Treatment outcomes of 125I low-dose-rate brachytherapy vs radical prostatectomy for patients with intermediate-risk prostate cancer

2020 ◽  
Author(s):  
Zhien Zhou ◽  
Meiting He ◽  
Yi Zhou ◽  
Weigang Yan ◽  
Xingcheng Wu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Dose Rate ◽  
Low Dose ◽  
Intermediate Risk ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Low Dose Rate ◽  
Risk Prostate Cancer ◽  
Low Dose Rate Brachytherapy

Abstract Background: Radical prostatectomy (RP) and low-dose-rate brachytherapy (LDR) are two widely used treatment options for patients with intermediate-risk prostate cancer (IRPC). However, which one is better remains controversial. Therefore, the purpose of this study was to compare the efficacy of RP vs LDR for patients with IRPC. Methods: A retrospective analysis was performed on 361 IRPC patients who underwent treatment from January 2010 and August 2017. 160 underwent RP and 201 underwent LDR using Iodine-125. Biochemical failure for RP was defined as prostate-specific antigen (PSA) levels > 0.2 ng/ml, and for LDR as nadir PSA level + 2 ng/ml. The log-rank test compared biochemical relapse-free survival (bRFS) between the two modalities, and Cox regression identified factors associated with bRFS. Results: Median follow-up was 54 months for RP and 69 months for LDR. The 5-and 8-year bRFS rates were 70.2% and 63.1% in the RP group, and 83.2% and 68.9% in the LDR group, respectively, P=0.003. There were no significant differences in terms of clinical relapse-free survival (cRFS), cancer-specific survival (CSS) or overall survival (OS) between the two groups. Conclusion: LDR is a reasonable treatment option for IRPC patients, yielding improved bRFS and equivalent rates of cRFS, CSS and OS compared with RP.

A comparison of overall and cause-specific survival among patients with low- and intermediate-risk prostate cancer treated with brachytherapy, external beam radiotherapy, or radical prostatectomy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5126-5126 ◽  
Author(s):  
J. P. Ciezki ◽  
C. A. Reddy ◽  
P. A. Kupelian ◽  
E. A. Klein ◽  
C. Robinson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
External Beam Radiotherapy ◽  
Smoking History ◽  
External Beam ◽  
Intermediate Risk ◽  
Charlson Score ◽  
Risk Of Death ◽  
Risk Prostate Cancer ◽  
Cause Specific Survival

5126 Background: The factors thought to influence overall survival (OS) and cause-specific survival (CSS) in patients treated for low and intermediate-risk prostate cancer (CaP) with brachytherapy (PI), external beam radiotherapy (RT), or radical prostatectomy (RP) were evaluated. Methods: From 1996 to 2003, 2285 patients with low or intermediate-risk CaP were treated at the Cleveland Clinic with either PI (n=662), RT (n=570), or RP (n=1053). Factors thought to influence OS and CSS were recorded. These factors included: Charlson score, age, socioeconomic status, race, body mass index (BMI), presence of coronary artery disease (CAD), presence of hypertension (HTN), presence of dyslipidemia (DL), initial prostate-specific antigen (iPSA), biopsy Gleason score (bGS), clinical stage, use of androgen deprivation (AD), AD duration, smoking history including pack-years, alcohol use, and cancer treatment modality (TX). Univariate and multivariate analyses were done using Cox proportional hazards regression. Results: The median follow-up is 59 months (range: 24–119 months). The 5- year OS rate is 96.0%, and the 8-year rate is 89.9%. Multivariate analysis revealed that Charlson score, age, smoking history, and TX were significantly associated with OS. Treatment with RT was independently associated with worse OS relative to PI and RP. CSS was grouped into 4 major categories: CAD, CaP, other cancer, and other. The only significant difference between these CSS categories and the treatment modalities was CaP. The percent of deaths due to CaP in the TX groups were: PI - 3.2%, RP - 9.7%, and RT - 24.5%. Conclusions: Charlson score, age, smoking history, and TX independently affect OS in patients treated for low and intermediate-risk CaP. The cause of the lower OS rate with RT may be related to an increased risk of death due to CaP. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document